Search | IOVS | ARVO Journals

Showing 1 – 20 of 20

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

In vitro and In vivo Sustained Release of Dexamethasone from Intravitreal Implants

Janet Tully; Mari Yang; Stuart Williams; Sanjib Das; Rozemarijn S Verhoeven; RiLee Robeson; Rhett M Schiffman; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4111. doi:

ARVO Annual Meeting Abstract June 2017

Extended release aflibercept with sustained vitreous concentration in non-human primates from biodegradable hydrogel implants

Gary Owens; Melissa Sandahl; Janet Tully; Jennifer Haley; Kwadwo Caesar; Stuart Williams; Rozemarijn S Verhoeven; Andres Garcia; Tomas Navratil; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):409. doi:

ARVO Annual Meeting Abstract June 2017

A 12-Month Study of the ENV515 (Travoprost) Intracameral Implant on Intraocular Pressure in Beagle Dogs

RiLee Robeson; Rozemarijn S Verhoeven; Andres Garcia; Sanjib Das; Kristie Hamby; Melissa Hernandez; Glenwood G Gum; Benjamin R Yerxa; Tomas Navratil

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1072. doi:

ARVO Annual Meeting Abstract June 2017

Extended PGA Delivery Results in Significant Drug Sparing Compared to Topical PGAs and Achieves Sustained IOP Lowering for 11 Months without Any Loss of Efficacy

Tomas Navratil; Jinny Conley; Rozemarijn S Verhoeven; Kristin Blackwell; Akshay Nadkarni; Leo Trevino; Benjamin R Yerxa; Michael Depenbusch; Tracey Knox; Iqbal Ahmad; Thomas R Walters; Steven L Mansberger

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2108. doi:

ARVO Annual Meeting Abstract June 2017

Interim Analysis of Low Dose ENV515 Travoprost XR with 11 Month Duration Followed by Dose Escalation and 28 Day Efficacy Evaluation of High Dose ENV515

Steven L Mansberger; Jinny Conley; Rozemarijn S Verhoeven; Kristin Blackwell; Michael Depenbusch; Tracey Knox; Thomas R Walters; Iqbal Ahmad; Benjamin R Yerxa; Tomas Navratil

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2110. doi:

ARVO Annual Meeting Abstract June 2017

Nonclinical Development of An Intravitreal Extended Release Implant for the Treatment of Diabetic Macular Edema

Stuart Williams; Rozemarijn S Verhoeven; Dustin Melton; Janet Tully; Sanjib Das; RiLee Robeson; Andres Garcia; Mari Yang; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4457. doi:

ARVO Annual Meeting Abstract September 2016

Precision Size and Shape Extended Release Intravitreal Dexamethasone Implants

Sanjib Kiumar Das; Stuart Williams; Janet Tully; Rozemarijn S Verhoeven; Mari Yang; Tomas Navratil; Rhett Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3278. doi:

ARVO Annual Meeting Abstract September 2016

A 6-Week Toxicity and Toxicokinetics Study of a Single Bilateral Intracameral Administration of ENV905 (difluprednate) Ophthalmic Implant in New Zealand White Rabbits

RiLee Robeson; Rozemarijn S Verhoeven; Andres Garcia; Paul Miller; Jacqueline Miller; Tomas Navratil; Rhett M Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4013. doi:

ARVO Annual Meeting Abstract September 2016

A 6-Week Ocular Pharmacokinetic Study of ENV905 (difluprednate) Intracameral Implant or Durezol in the Albino Rabbit

Rozemarijn S Verhoeven; RiLee Robeson; Andres Garcia; Brian C Gilger; David Culp; Craig B Struble; Lee Hamm; Thomas Grizzle; Tomas Navratil; Rhett M Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5711. doi:

ARVO Annual Meeting Abstract September 2016

In vitro and In vivo Sustained Release of Dexamethasone from a PRINT Microparticle Suspension

Melissa Sandahl; Melissa Hernandez; Janet Tully; Gary owens; Rozemarijn S Verhoeven; RiLee Robeson; Stuart Williams; Rhett Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4023. doi:

ARVO Annual Meeting Abstract September 2016

Design and Development of ENV515 Intraocular Applicator for Intracameral Injections of ENV515 Glaucoma Extended Release (XR) Therapy

Tomas Navratil; Jessie Delgado; Andres Garcia; Gretchen Willard; Andrew Corson; Rozemarijn S Verhoeven; Leo Trevino; Rhett Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3021. doi:

ARVO Annual Meeting Abstract June 2015

Fabrication of Shape and Size Specific Nanoparticles for Ocular Drug Delivery

Stuart Williams; Sanjib Das; Jeremy Hansen; Janet Tully; Melissa Hernandez; Tyler Pegoraro; Rozemarijn S Verhoeven; Benjamin Maynor; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5026. doi:

ARVO Annual Meeting Abstract June 2015

Advancing ENV515 (travoprost) Intracameral Implant into Clinical Development: Nonclinical Evaluation of ENV515 in Support of First-Time-in-Human Phase 2a Clinical Study

Tomas Navratil; Andres Garcia; Rozemarijn S Verhoeven; Leo Trevino; Brian C Gilger; Steven L Mansberger; Donald L Budenz; Iqbal Ike K. Ahmed; Richard A. Lewis; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5706. doi:

ARVO Annual Meeting Abstract June 2015

Preclinical Evaluation of ENV905 (Difluprednate) Ophthalmic Implant: A Clinical Candidate for the Treatment of Pain and Inflammation Associated with Ocular Surgery

Andres Garcia; Rozemarijn S Verhoeven; Tyler Pegoraro; Jeremy Hansen; Jinny Conley; Rilee Robeson; Brian C Gilger; Tomas Navratil; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5897. doi:

ARVO Annual Meeting Abstract June 2015

ESTABLISHING IN VIVO TO IN VITRO CORRELATIONS FOR THE RATE OF RELEASE OF BEVACIZUMAB FROM EXTENDED RELEASE FORMULATIONS

Gary Owens; Stuart Williams; Kevin Herlihy; Janet Tully; Rozemarijn S Verhoeven; Tomas Navratil; Benjamin Maynor; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):236. doi:

ARVO Annual Meeting Abstract June 2015

EXTENDED RELEASE BEVACIZUMAB INTRAVITREAL IMPLANT IS WELL TOLERATED IN THE AFRICAN GREEN MONKEY

Rozemarijn S Verhoeven; Stuart Williams; Jinny Conley; Gary Owens; Matthew S Lawrence; Tomas Navratil; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):230. doi:

ARVO Annual Meeting Abstract April 2014

Safety and Tolerability of Drugs Within the Suprachoroidal Space in Albino Rabbits

Samirkumar Rajnikant Patel; Rozemarijn S Verhoeven; Brian Burke; Fllorian Cacciamani; Karen Viaud; Henry F Edelhauser

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):4886. doi:

ARVO Annual Meeting Abstract April 2014

Safety and toxicokinetics of suprachoroidal space (SCS) injections of CLS1001 (triamcinolone acetonide, TA) in albino rabbits

Glenn Noronha; Henry F Edelhauser; Samir Patel; Brian Burke; Rozemarijn S Verhoeven

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):4887. doi:

ARVO Annual Meeting Abstract April 2014

Characterization of sodium fluorescein administered into the suprachoroidal space of nonhuman primates using a microneedle

Vladimir Zarnitsyn; Samirkumar Rajnikant Patel; Rozemarijn S Verhoeven; Matthew S Lawrence

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5258. doi:

ARVO Annual Meeting Abstract April 2014

Intraocular Distribution and Targeting of Triamcinolone Acetonide Suspension Administered Into the Suprachoroidal Space

Henry F Edelhauser; Rozemarijn S Verhoeven; Brian Burke; Craig B Struble; Samirkumar Rajnikant Patel

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5259. doi:

NARROW

Content Type

Journal

Article Type

Specify Date Range

In vitro and In vivo Sustained Release of Dexamethasone from Intravitreal Implants

Extended release aflibercept with sustained vitreous concentration in non-human primates from biodegradable hydrogel implants

A 12-Month Study of the ENV515 (Travoprost) Intracameral Implant on Intraocular Pressure in Beagle Dogs

Extended PGA Delivery Results in Significant Drug Sparing Compared to Topical PGAs and Achieves Sustained IOP Lowering for 11 Months without Any Loss of Efficacy

Interim Analysis of Low Dose ENV515 Travoprost XR with 11 Month Duration Followed by Dose Escalation and 28 Day Efficacy Evaluation of High Dose ENV515

Nonclinical Development of An Intravitreal Extended Release Implant for the Treatment of Diabetic Macular Edema

Precision Size and Shape Extended Release Intravitreal Dexamethasone Implants

A 6-Week Toxicity and Toxicokinetics Study of a Single Bilateral Intracameral Administration of ENV905 (difluprednate) Ophthalmic Implant in New Zealand White Rabbits

A 6-Week Ocular Pharmacokinetic Study of ENV905 (difluprednate) Intracameral Implant or Durezol in the Albino Rabbit

In vitro and In vivo Sustained Release of Dexamethasone from a PRINT Microparticle Suspension

Design and Development of ENV515 Intraocular Applicator for Intracameral Injections of ENV515 Glaucoma Extended Release (XR) Therapy

Fabrication of Shape and Size Specific Nanoparticles for Ocular Drug Delivery

Advancing ENV515 (travoprost) Intracameral Implant into Clinical Development: Nonclinical Evaluation of ENV515 in Support of First-Time-in-Human Phase 2a Clinical Study

Preclinical Evaluation of ENV905 (Difluprednate) Ophthalmic Implant: A Clinical Candidate for the Treatment of Pain and Inflammation Associated with Ocular Surgery

ESTABLISHING IN VIVO TO IN VITRO CORRELATIONS FOR THE RATE OF RELEASE OF BEVACIZUMAB FROM EXTENDED RELEASE FORMULATIONS

EXTENDED RELEASE BEVACIZUMAB INTRAVITREAL IMPLANT IS WELL TOLERATED IN THE AFRICAN GREEN MONKEY

Safety and Tolerability of Drugs Within the Suprachoroidal Space in Albino Rabbits

Safety and toxicokinetics of suprachoroidal space (SCS) injections of CLS1001 (triamcinolone acetonide, TA) in albino rabbits

Characterization of sodium fluorescein administered into the suprachoroidal space of nonhuman primates using a microneedle

Intraocular Distribution and Targeting of Triamcinolone Acetonide Suspension Administered Into the Suprachoroidal Space

To View More...

You must be signed into an individual account to use this feature.